

RealRate

PHARMACEUTICAL 2020



Deciphera Pharmaceuticals Inc. Rank 51 of 358







PHARMACEUTICAL 2020



## RealRate

## Deciphera Pharmaceuticals Inc. Rank 51 of 358

The relative strengths and weaknesses of Deciphera Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Deciphera Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 97% points. The greatest weakness of Deciphera Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 214%, being 178% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	593,408
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	60,038
Liabilities, Non-Current	15,904
Other Assets	22,668
Other Compr. Net Income	111
Other Expenses	0
Other Liabilities	0
Other Net Income	8,470
Other Revenues	25,000
Property and Equipment	6,333
Research and Development	157,610
Selling, General and Administrative Expense	68,116

Output Variable	Value in 1000 USD
Assets	622,409
Liabilities	75,942
Expenses	225,726
Revenues	25,000
Stockholders Equity	546,467
Net Income	-192,256
Comprehensive Net Income	-192,200
Economic Capital Ratio	214%

